Yan Tereshko, Simone Dal Bello, Enrico Belgrado, Cherubino Di Lorenzo, Alice Pittino, Francesca Filippi, Francesca Valdemarin, Christian Lettieri, Gian Luigi Gigli, Annacarmen Nilo, Gaia Pellitteri, Giovanni Merlino, Mariarosaria Valente
{"title":"生酮饮食改善慢性偏头痛患者的睡眠质量和白天嗜睡：一项试点研究","authors":"Yan Tereshko, Simone Dal Bello, Enrico Belgrado, Cherubino Di Lorenzo, Alice Pittino, Francesca Filippi, Francesca Valdemarin, Christian Lettieri, Gian Luigi Gigli, Annacarmen Nilo, Gaia Pellitteri, Giovanni Merlino, Mariarosaria Valente","doi":"10.3390/neurolint16060091","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The aim of this study is to assess the sleep quality and daytime sleepiness improvement in chronic migraineurs after 6 months of a 2:1 KD (ketogenic diet) and LGID (low-glycemic-index diet).</p><p><strong>Methods: </strong>Twenty-six patients underwent 2:1 KD (11 patients) and LGID (15 patients). PSQI (Pittsburgh sleep quality index) and ESS (Epworth sleepiness scale) were administered at the baseline and the 3-month and 6-month follow-up. MIDAS (Migraine Disability Assessment), HIT-6 (Headache Impact Test 6), migraine frequency (migraine days per month), migraine intensity, BMI (Body Mass Index), FM (Fat Mass), and FFM (Fat-Free Mass) were also assessed.</p><p><strong>Results: </strong>PSQI (F<sub>1.544, 38.606</sub> = 7.250; <i>p</i> = 0.004), ESS (F<sub>1.988, 49.708</sub> = 9.938; <i>p</i> < 0.001), HIT-6 (F<sub>1.432, 35.805</sub> = 12.693; <i>p</i> < 0.001), migraine frequency (F<sub>1.522, 38.041</sub> = 23.070; <i>p</i> < 0.001), migraine intensity (F<sub>1.949, 48.721</sub> = 18.798; <i>p</i> < 0.001), BMI (F<sub>1.274, 31.857</sub> = 38.191; <i>p</i> < 0.001), and FM (F<sub>1.245, 31.134</sub> = 45.487; <i>p</i> < 0.001) improved significantly. The MIDAS (F<sub>1.005, 25.121</sub> = 3.037; <i>p</i> = 0.093) and the FMM (F<sub>1.311, 32.784</sub> = 1.741; <i>p</i> = 0.197) did not improve significantly. The ESS (<i>p</i> = 0.712) and PSQI (<i>p</i> = 0.776) data at 3-month and 6-month follow-ups did not differ significantly, as well as for migraine frequency, migraine intensity, BMI, FM, and HIT-6. A mild correlation emerged between the mean FM and mean ESS reduction during the 6 months (<i>r</i> = 0.497, <i>p</i> = 0.010).</p><p><strong>Conclusions: </strong>Six months of LGID and 2:1 KD can improve sleep quality and daytime sleepiness in patients with chronic migraine. The effectiveness on migraine, sleep quality, and daytime sleepiness does not differ significantly between the 3-month and 6-month follow-up periods.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"16 6","pages":"1203-1213"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587072/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ketogenic Diet Improves Sleep Quality and Daytime Sleepiness in Chronic Migraine: A Pilot Study.\",\"authors\":\"Yan Tereshko, Simone Dal Bello, Enrico Belgrado, Cherubino Di Lorenzo, Alice Pittino, Francesca Filippi, Francesca Valdemarin, Christian Lettieri, Gian Luigi Gigli, Annacarmen Nilo, Gaia Pellitteri, Giovanni Merlino, Mariarosaria Valente\",\"doi\":\"10.3390/neurolint16060091\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>The aim of this study is to assess the sleep quality and daytime sleepiness improvement in chronic migraineurs after 6 months of a 2:1 KD (ketogenic diet) and LGID (low-glycemic-index diet).</p><p><strong>Methods: </strong>Twenty-six patients underwent 2:1 KD (11 patients) and LGID (15 patients). PSQI (Pittsburgh sleep quality index) and ESS (Epworth sleepiness scale) were administered at the baseline and the 3-month and 6-month follow-up. MIDAS (Migraine Disability Assessment), HIT-6 (Headache Impact Test 6), migraine frequency (migraine days per month), migraine intensity, BMI (Body Mass Index), FM (Fat Mass), and FFM (Fat-Free Mass) were also assessed.</p><p><strong>Results: </strong>PSQI (F<sub>1.544, 38.606</sub> = 7.250; <i>p</i> = 0.004), ESS (F<sub>1.988, 49.708</sub> = 9.938; <i>p</i> < 0.001), HIT-6 (F<sub>1.432, 35.805</sub> = 12.693; <i>p</i> < 0.001), migraine frequency (F<sub>1.522, 38.041</sub> = 23.070; <i>p</i> < 0.001), migraine intensity (F<sub>1.949, 48.721</sub> = 18.798; <i>p</i> < 0.001), BMI (F<sub>1.274, 31.857</sub> = 38.191; <i>p</i> < 0.001), and FM (F<sub>1.245, 31.134</sub> = 45.487; <i>p</i> < 0.001) improved significantly. The MIDAS (F<sub>1.005, 25.121</sub> = 3.037; <i>p</i> = 0.093) and the FMM (F<sub>1.311, 32.784</sub> = 1.741; <i>p</i> = 0.197) did not improve significantly. The ESS (<i>p</i> = 0.712) and PSQI (<i>p</i> = 0.776) data at 3-month and 6-month follow-ups did not differ significantly, as well as for migraine frequency, migraine intensity, BMI, FM, and HIT-6. A mild correlation emerged between the mean FM and mean ESS reduction during the 6 months (<i>r</i> = 0.497, <i>p</i> = 0.010).</p><p><strong>Conclusions: </strong>Six months of LGID and 2:1 KD can improve sleep quality and daytime sleepiness in patients with chronic migraine. The effectiveness on migraine, sleep quality, and daytime sleepiness does not differ significantly between the 3-month and 6-month follow-up periods.</p>\",\"PeriodicalId\":19130,\"journal\":{\"name\":\"Neurology International\",\"volume\":\"16 6\",\"pages\":\"1203-1213\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587072/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/neurolint16060091\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/neurolint16060091","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Ketogenic Diet Improves Sleep Quality and Daytime Sleepiness in Chronic Migraine: A Pilot Study.
Aims: The aim of this study is to assess the sleep quality and daytime sleepiness improvement in chronic migraineurs after 6 months of a 2:1 KD (ketogenic diet) and LGID (low-glycemic-index diet).
Methods: Twenty-six patients underwent 2:1 KD (11 patients) and LGID (15 patients). PSQI (Pittsburgh sleep quality index) and ESS (Epworth sleepiness scale) were administered at the baseline and the 3-month and 6-month follow-up. MIDAS (Migraine Disability Assessment), HIT-6 (Headache Impact Test 6), migraine frequency (migraine days per month), migraine intensity, BMI (Body Mass Index), FM (Fat Mass), and FFM (Fat-Free Mass) were also assessed.
Results: PSQI (F1.544, 38.606 = 7.250; p = 0.004), ESS (F1.988, 49.708 = 9.938; p < 0.001), HIT-6 (F1.432, 35.805 = 12.693; p < 0.001), migraine frequency (F1.522, 38.041 = 23.070; p < 0.001), migraine intensity (F1.949, 48.721 = 18.798; p < 0.001), BMI (F1.274, 31.857 = 38.191; p < 0.001), and FM (F1.245, 31.134 = 45.487; p < 0.001) improved significantly. The MIDAS (F1.005, 25.121 = 3.037; p = 0.093) and the FMM (F1.311, 32.784 = 1.741; p = 0.197) did not improve significantly. The ESS (p = 0.712) and PSQI (p = 0.776) data at 3-month and 6-month follow-ups did not differ significantly, as well as for migraine frequency, migraine intensity, BMI, FM, and HIT-6. A mild correlation emerged between the mean FM and mean ESS reduction during the 6 months (r = 0.497, p = 0.010).
Conclusions: Six months of LGID and 2:1 KD can improve sleep quality and daytime sleepiness in patients with chronic migraine. The effectiveness on migraine, sleep quality, and daytime sleepiness does not differ significantly between the 3-month and 6-month follow-up periods.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
